Outset Medical Secures $91 Million for Kidney Dialysis System

Outset Medical has secured $91 million in equity and debt funding to further commercialize its Tablo dialysis system.

The automated system, which features wireless connectivity and real-time integrated water purification, received FDA clearance for acute and chronic care settings in May. The agency also approved a clinical trial to evaluate the system’s efficacy.

The San Jose, Calif., plans to use the money for a limited commercial launch this year and to pursue expanded FDA approval, which would allow patients to operate the device in their homes.

The Fidelity Research and Management Company, Warburg Pincus, The Vertical Group, Partner Fund Management LP, Perceptive Advisors and CRG all shepherded the financing.

An estimated 26 million people in the U.S. suffer from chronic kidney disease, potentially requiring dialysis. — Jason Scott